We are live on ! Find out more
NXTC icon

NextCure
NXTC

38 hedge funds and large institutions have $7.38M invested in NextCure in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 9

0.2% less ownership

Funds ownership: 4.77% → 4.57% (-0.2%)

16% less funds holding

Funds holding: 45 → 38 (-7)

44% less capital invested

Capital invested by funds: $13.1M → $7.38M (-$5.75M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 7

Holders
38
Holders Change
-7
Holders Change %
-15.56%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
9
Reduced
9
Closed
7
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
+$1K

Top Buyers

Rank Fund Capital Flow
1
P
Pfizer
New York
+$318K
2
CCC
Cable Car Capital
California
+$39.9K
3
Citigroup
Citigroup
New York
+$22.3K
4
Citadel Advisors
Citadel Advisors
Florida
+$8.79K
5
XT
XTX Topco
Cayman Islands
+$3.27K

Top Sellers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
-$217K
2
LFCM
Long Focus Capital Management
Puerto Rico
-$143K
3
BlackRock
BlackRock
New York
-$126K
4
PLC
Peapod Lane Capital
New York
-$102K
5
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$83K
Name Holding Trade Value Shares
Change 		Change in
Stake
SI
1
Sofinnova Investments
California
$1.28M – – –
AAA
2
Affinity Asset Advisors
New York
$1.11M – – –
P
3
Pfizer
New York
$909K +$318K +36,101 +30%
Citigroup
4
Citigroup
New York
$682K +$22.3K +2,528 +2%
O
5
OrbiMed
New York
$548K – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$474K – – –
CCC
7
Cable Car Capital
California
$322K +$39.9K +4,519 +9%
BlackRock
8
BlackRock
New York
$267K -$126K -14,241 -23%
Acadian Asset Management
9
Acadian Asset Management
Massachusetts
$233K – – –
Renaissance Technologies
10
Renaissance Technologies
New York
$231K -$28.9K -3,278 -8%
TCM
11
Tang Capital Management
California
$194K -$217K -24,654 -42%
Federated Hermes
12
Federated Hermes
Pennsylvania
$151K – – –
BCM
13
BML Capital Management
Indiana
$131K – – –
PLC
14
Peapod Lane Capital
New York
$127K -$102K -11,522 -34%
CPA
15
Cardiff Park Advisors
California
$126K – – –
Geode Capital Management
16
Geode Capital Management
Massachusetts
$113K +$1.67K +189 +1%
Macquarie Group
17
Macquarie Group
Australia
$72K – – –
SCM
18
Sio Capital Management
New York
$62.4K – – –
ACM
19
ADAR1 Capital Management
Texas
$57.6K – – –
AC
20
Armistice Capital
New York
$50K – – –
Citadel Advisors
21
Citadel Advisors
Florida
$43.5K +$8.79K +997 +15%
Barclays
22
Barclays
United Kingdom
$32.4K – – –
State Street
23
State Street
Massachusetts
$31.4K – – –
BCM
24
Bridgeway Capital Management
Texas
$24.8K -$11.7K -1,325 -24%
Northern Trust
25
Northern Trust
Illinois
$22.8K – – –
1
2

NXTC Hedge Fund Activity: Q1 2025 in Review

38 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q1 2025, worth a combined $7.38M — down 44% from $13.1M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of NXTC and 0 opened new positions — a net loss of 7 holders — while 9 trimmed existing stakes and 9 added.

The largest buyer was Pfizer, adding an estimated $318K. The largest seller was Tang Capital Management, cutting an estimated $217K.

  • 38 institutional investors held NextCure (NXTC) as of Q1 2025, down from 45 in Q4 2024.
  • Funds reported $7.38M of NextCure stock for Q1 2025, down 44% quarter-over-quarter.
  • 0 funds opened new NextCure positions in Q1 2025 and 7 closed out, a net change of -7 holders.
  • The largest NextCure buyer in Q1 2025 was Pfizer, an estimated $318K added.
  • The largest NextCure seller in Q1 2025 was Tang Capital Management, an estimated $217K sold.

Based on aggregated 13F filings for Q1 2025.